ROS1 protein inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “ROS1 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in ROS1 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
ROS1 protein inhibitors: Overview
ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase.
Report Highlights
This segment of the ROS1 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ROS1 protein inhibitors Emerging Drugs
Further product details are provided in the report……..
ROS1 protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different ROS1 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
ROS1 protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses ROS1 protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ROS1 protein inhibitors drugs.
ROS1 protein inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “ROS1 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in ROS1 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
ROS1 protein inhibitors: Overview
ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence ROS1 protein inhibitors R&D. The therapies under development are focused on novel approaches for ROS1 protein inhibitors.
This segment of the ROS1 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ROS1 protein inhibitors Emerging Drugs
- Alkotinib: Suzhou Zelgen Biopharmaceuticals
- APG-2449: Ascentage Pharma
Further product details are provided in the report……..
ROS1 protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different ROS1 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on ROS1 protein inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
ROS1 protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses ROS1 protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ROS1 protein inhibitors drugs.
ROS1 protein inhibitors Report Insights
- ROS1 protein inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing ROS1 protein inhibitors drugs?
- How many ROS1 protein inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ROS1 protein inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ROS1 protein inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for ROS1 protein inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Suzhou Zelgen Biopharmaceuticals
- Ascentage Pharma
- Xuanzhu Biopharmaceutical
- Pfizer
- Turning Point Therapeutics
- Roche
- Fochon Pharma
- Eli Lilly and Company
- Daiichi Sankyo Inc
- Chia Tai Tianqing Pharmaceutical Group
- Xcovery
- Alkotinib
- APG-2449
- XZP 3621
- Lorlatinib
- Crizotinib
- Repotrectinib
- Entrectinib
- TQ B3101
- Foritinib succinate
- Taletrectinib
- Merestinib
- Ensartinib
Introduction
Executive Summary
ROS1 protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ROS1 protein inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Ensartinib: Xcovery
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Alkotinib: Suzhou Zelgen Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
APG-2449: Ascentage Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
ROS1 protein inhibitors Key Companies
ROS1 protein inhibitors Key Products
ROS1 protein inhibitors- Unmet Needs
ROS1 protein inhibitors- Market Drivers and Barriers
ROS1 protein inhibitors- Future Perspectives and Conclusion
ROS1 protein inhibitors Analyst Views
ROS1 protein inhibitors Key Companies
Appendix
Executive Summary
ROS1 protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ROS1 protein inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Ensartinib: Xcovery
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Alkotinib: Suzhou Zelgen Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
APG-2449: Ascentage Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
ROS1 protein inhibitors Key Companies
ROS1 protein inhibitors Key Products
ROS1 protein inhibitors- Unmet Needs
ROS1 protein inhibitors- Market Drivers and Barriers
ROS1 protein inhibitors- Future Perspectives and Conclusion
ROS1 protein inhibitors Analyst Views
ROS1 protein inhibitors Key Companies
Appendix